Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation

Br J Haematol. 2001 Sep;114(4):931-6. doi: 10.1046/j.1365-2141.2001.03013.x.

Abstract

Disparity for the minor histocompatibility antigen HA-1 between patient and donor has been associated with an increased risk of acute graft-versus-host disease (GvHD) after allogeneic human leucocyte antigen (HLA)-identical sibling donor stem cell transplantation (SCT). However, no data concerning the impact of such disparity on chronic GvHD, relapse or overall survival are available. A retrospective multicentre study was performed on 215 HLA-A2-positive patients who received an HLA-identical sibling SCT, in order to determine the differences in acute and chronic GvHD incidence on the basis of the presence or absence of the HA-1 antigen mismatch. Disease-free survival and overall survival were also analysed. We detected 34 patient-donor pairs mismatched for HA-1 antigen (15.8%). Grades II-IV acute GvHD occurred in 51.6% of the HA-1-mismatched pairs compared with 37.1% of the non-mismatched. The multivariate logistic regression model showed statistical significance (P: 0.035, OR: 2.96, 95% CI: 1.07-8.14). No differences were observed between the two groups for grades III-IV acute GvHD, chronic GvHD, disease-free survival or overall survival. These results confirmed the association between HA-1 mismatch and risk of mild acute GvHD, but HA-1 mismatch was not associated with an increased incidence of chronic GvHD and did not affect relapse or overall survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Anemia, Aplastic / immunology
  • Anemia, Aplastic / therapy
  • Chi-Square Distribution
  • Chronic Disease
  • Disease-Free Survival
  • Female
  • Graft vs Host Disease / immunology*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia / immunology
  • Leukemia / therapy*
  • Logistic Models
  • Lymphoma, Non-Hodgkin / immunology
  • Lymphoma, Non-Hodgkin / therapy
  • Male
  • Middle Aged
  • Minor Histocompatibility Antigens / immunology*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / therapy
  • Myelodysplastic Syndromes / immunology
  • Myelodysplastic Syndromes / therapy
  • Oligopeptides
  • Survival Rate
  • Transplantation Immunology*

Substances

  • HA-1 antigen
  • Minor Histocompatibility Antigens
  • Oligopeptides